|Adj. Assoc. Prof. Danny Soon is Chief Executive Officer at the Consortium for Clinical Research and Innovation, Singapore (CRIS), concurrent Executive Director at the Singapore Clinical Research Institute (SCRI) and also the Interim Executive Director, Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). A/Prof Soon was previously the Executive Director of Biomedical Research Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. A/Prof Soon also held the role of founding and Acting CEO of the Experimental Biotherapeutics Centre. Danny has long experience in drug development, having worked at Eli Lilly and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical Pharmacology (LNUS).|
The last 2 decades have seen giant leaps and transformations in the biopharma and lifesciences industry. At the start of the 21st Century, drug hunting and drug making still bore many of the vestiges of the prior century. However, with the completion of the human genome project, the exponential growth of computational power and availability thereof, and the advent of AI, the development and commercialisation of novel medicines has undergone a tremendous revolution. How does one keep up?